ArticlePolymers2025
Sourcing Interchangeability in Commercial Chitosan: Focus on the Physical-Chemical Properties of Six Different Products and Their Impact on the Release of Antibacterial Agents.
Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Translational Barriers to Pharmaceutical Excipient Readiness in Marine-Derived Polymers.Polymers · 2026Review
- Long-term moxifloxacin release from a chitosan-based antibacterial coating on polyethylene for biomedical applications.RSC advances · 2026Article
- Article
- Effect of Chitosan Properties and Dissolution State on Solution Rheology and Film Performance in Triboelectric Nanogenerators.Gels (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Sourcing and batch differences are often cited as intrinsic drawbacks for all natural polymers. Chitosan makes no exception. Chitosan is a biocompatible and biodegradable biopolymer with high potential for several biomedical applications, especially for releasing drugs and bactericidal and virucidal agents. Despite the potential of chitosan as a matrix for producing antibacterial films, the variability in its composition, stemming from its natural sources, can hinder the translation from bench to industry. To overcome this concern, we conducted a study to access the interchangeability of chitosan for the development of antibacterial drug release systems, in particular one system crosslinked with tannic acid and iron sulfate. Chitosans from different suppliers were characterized and used to synthetize films containing gentamicin, according to a previously reported protocol. The impact of molecular weight (M
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.